19 related articles for article (PubMed ID: 30017795)
1. Response to A. Chauhan and A. Pal.
Matikas A; Georgoulias V
Br J Cancer; 2022 Jun; 126(11):1661-1662. PubMed ID: 35379931
[No Abstract] [Full Text] [Related]
2. CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Rack B; Jückstock J; Trapp E; Weissenbacher T; Alunni-Fabbroni M; Schramm A; Widschwendter P; Lato K; Zwingers T; Lorenz R; Tesch H; Schneeweiss A; Fasching P; Mahner S; Beckmann MW; Lichtenegger W; Janni W;
Tumour Biol; 2016 Oct; 37(10):13769-13775. PubMed ID: 27481512
[TBL] [Abstract][Full Text] [Related]
3. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
[TBL] [Abstract][Full Text] [Related]
4. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial.
Bekes I; Eichler M; Singer S; Friedl TWP; Harbeck N; Rack B; Forstbauer H; Dannecker C; Huober J; Kiechle M; Lato K; Janni W; Fink V
Clin Breast Cancer; 2020 Dec; 20(6):439-447. PubMed ID: 32800493
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
7. Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
Hepp P; Fasching PA; Beckmann MW; Fehm T; Salmen J; Hagenbeck C; Jäger B; Widschwendter P; de Gregorio N; Schochter F; Mahner S; Harbeck N; Weissenbacher T; Kurt AG; Friedl TWP; Janni W; Rack B
Clin Breast Cancer; 2018 Oct; 18(5):e1103-e1110. PubMed ID: 30017795
[TBL] [Abstract][Full Text] [Related]
8. [Role of G-CSF for breast cancer chemotherapy].
Suzuki Y; Saito Y; Tokuda Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():572-4. PubMed ID: 17679213
[No Abstract] [Full Text] [Related]
9. Review of clinical studies of CA 27.29 in breast cancer management.
Beveridge RA
Int J Biol Markers; 1999; 14(1):36-9. PubMed ID: 10367248
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]